USFDA10 Jul 2024, 08:52 pm
Zydus Lifesciences Receives Final Approval from USFDA for Sacubitril and Valsartan Tablets
AI Summary
Zydus Lifesciences Ltd has received final approval from the USFDA to market Sacubitril and Valsartan Tablets in the US. The drug, used to treat chronic heart failure, will be manufactured at the company's facility in India. With this approval, Zydus now has 399 approvals and has filed over 460 ANDAs since 2003-04.
Key Highlights
- Zydus receives final approval from USFDA for Sacubitril and Valsartan Tablets
- Sacubitril and Valsartan Tablets to be used for treating chronic heart failure
- Manufacturing to take place at Zydus' facility in India
- Zydus now has 399 approvals and has filed over 460 ANDAs